Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 Jan 30

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 Jan 30

DOI: 10.23736/S1824-4785.18.03062-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

The future of choline pet in the era of PMSA

Laura EVANGELISTA 1 , Lea CUPPARI 1, Fabio ZATTONI 2, 3, Luigi MANSI 4, Emilio BOMBARDIERI 5

1 Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy; 2 Academic Medical Centre Hospital Santa Maria della Misericordia, Udine, Italy; 3 PhD Course in Clinical and Experimental Oncology and Immunology, Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy; 4 Interuniversitary Research Center for Sustainable Development (CIRPS), Napoli-Roma, Roma, Italy; 5 Scientific Direction, Cliché Humanitas Gavazzeni, Bergamo, Italy


PDF  


Radiolabeled choline was the first radiopharmaceutical agent employed in prostate cancer patients. It has been considered a metabolic agent able to detect the presence of prostate cancer cell, both in the initial phase of the disease and in the restaging setting. Three agents are now available in clinical practice: one radiolabeled with 11C (called 11C-Choline) and two with 18F (either as 18F-methylcholine or 18F-ethylcholine). During the years, different studies have been performed with 11C -Choline and 18F- Choline demonstrating their performance for the detection of prostate cancer, in different settings of the disease. However, recently, new radiopharmaceutical agents for prostate cancer have been developed, gaining an important role for the diagnosis of prostate cancer, particularly in the restaging setting. The present review has been conceived in order to discuss the current role of radiolabeled choline PET/CT in the era of new agents for prostate cancer, in particular in the era of radiolabeled PSMA.


KEY WORDS: Prostate neoplasm - Fluoromethylcholine - Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))

inizio pagina

Publication History

Article first published online: January 30, 2018
Manuscript accepted: January 29, 2018
Manuscript received: December 19, 2017

Per citare questo articolo

Evangelista L, Cuppari L, Zattoni F, Mansi L, Bombardieri E. The future of choline pet in the era of PMSA. Q J Nucl Med Mol Imaging 2018 Jan 30. DOI: 10.23736/S1824-4785.18.03062-5

Corresponding author e-mail

laura.evangelista@iov.veneto.it